This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (43)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Randomized Controlled Trial  • Alert me on articles by topic  Social Bookmarking   What's this?

The TEMPO Study

Parkinson Study Group

Arch Neurol. 2002;59:1937-1943.

Context  Monotherapy with rasagiline mesylate may be useful in early Parkinson disease (PD).

Objective  To evaluate the safety and efficacy of the selective monoamine oxidase type B inhibitor rasagiline.

Design  Multicenter, 26-week, parallel-group, randomized, double-blind, placebo-controlled clinical trial.

Setting  Academically based movement disorders clinics.

Patients  Patients with early PD not requiring dopaminergic therapy (n = 404).

Intervention  Research participants were randomized to rasagiline mesylate at dosages of 1 mg or 2 mg per day or matching placebo. A 1-week escalation period was followed by a 25-week maintenance period.

Main Outcome Measure  The primary prespecified measure of efficacy was the change in the total Unified Parkinson's Disease Rating Scale score between baseline and 26 weeks of treatment, comparing each active treatment group with the placebo group.

Results  Monotherapy with rasagiline was effective in this 26-week study. The adjusted effect size for the total Unified Parkinson's Disease Rating Scale was -4.20 units comparing 1 mg of rasagiline and placebo (95% confidence interval, -5.66 to -2.73 units; P<.001) and -3.56 units comparing a 2-mg dosage and placebo (95% confidence interval, -5.04 to -2.08 units; P<.001). There were no meaningful differences in the frequency of adverse events or premature withdrawals among the treatment groups.

Conclusions  Rasagiline is effective as monotherapy for patients with early PD. The 2 dosages in this trial were both effective relative to placebo. Further study is warranted to evaluate the longer-term effects of rasagiline in PD.

This study was supported by Teva Pharmaceutical Industries, Ltd.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow et al.
Neurology 2009;72:S1-S136.
ABSTRACT | FULL TEXT  

Diagnosis and the premotor phase of Parkinson disease
Tolosa et al.
Neurology 2009;72:S12-S20.
ABSTRACT | FULL TEXT  

Mechanisms compensating for dopamine loss in early Parkinson disease
Brotchie and Fitzer-Attas
Neurology 2009;72:S32-S38.
ABSTRACT | FULL TEXT  

When and how should treatment be started in Parkinson disease?
Lang
Neurology 2009;72:S39-S43.
ABSTRACT | FULL TEXT  

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?
Olanow
Neurology 2009;72:S59-S64.
ABSTRACT | FULL TEXT  

Transtelephonic Home Blood Pressure to Assess the Monoamine Oxidase-B Inhibitor Rasagiline in Parkinson Disease
White et al.
Hypertension 2008;52:587-593.
ABSTRACT | FULL TEXT  

Pharmacologic Management of Parkinson Disease: Choice of Initial Therapy in Early Disease
Chen and Pahwa
Journal of Pharmacy Practice 2008;21:244-253.
ABSTRACT  

A review of Parkinson's disease
Davie
Br Med Bull 2008;86:109-127.
ABSTRACT | FULL TEXT  

Treatment Options in the Modern Management of Parkinson Disease
Schapira
Arch Neurol 2007;64:1083-1088.
FULL TEXT  

New pharmacologic horizons in the treatment of Parkinson disease.
Bonuccelli and Del Dotto
Neurology 2006;67:S30-S38.
ABSTRACT | FULL TEXT  

Issues in neuroprotection clinical trials in Parkinson's disease
Kieburtz
Neurology 2006;66:S50-S57.
ABSTRACT | FULL TEXT  

Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease
Chen and Ly
Am J Health Syst Pharm 2006;63:915-928.
ABSTRACT | FULL TEXT  

Safety of rasagiline in elderly patients with Parkinson disease
Goetz et al.
Neurology 2006;66:1427-1429.
ABSTRACT | FULL TEXT  

Selegiline slows the progression of the symptoms of Parkinson disease
Palhagen et al.
Neurology 2006;66:1200-1206.
ABSTRACT | FULL TEXT  

Cost-Utility Model of Rasagiline in the Treatment of Advanced Parkinson's Disease in Finland
Hudry et al.
The Annals of Pharmacotherapy 2006;40:651-657.
ABSTRACT | FULL TEXT  

Present and future drug treatment for Parkinson's disease
Schapira
J. Neurol. Neurosurg. Psychiatry 2005;76:1472-1478.
ABSTRACT | FULL TEXT  

In Vivo Measurement of Brain Monoamine Oxidase B Occupancy by Rasagiline, Using 11C-L-Deprenyl and PET
Freedman et al.
JNM 2005;46:1618-1624.
ABSTRACT | FULL TEXT  

Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease
Chen and Swope
J Clin Pharmacol 2005;45:878-894.
ABSTRACT | FULL TEXT  

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients With Parkinson Disease and Motor Fluctuations: The PRESTO Study
Parkinson Study Group
Arch Neurol 2005;62:241-248.
ABSTRACT | FULL TEXT  

The comparative effects of medical therapies for Parkinson's disease
Horn and Stern
Neurology 2004;63:S7-S12.
FULL TEXT  

A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease
Youdim and Riederer
Neurology 2004;63:S32-S35.
FULL TEXT  

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
Ives et al.
BMJ 2004;329:593.
ABSTRACT | FULL TEXT  

A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
Parkinson Study Group
Arch Neurol 2004;61:561-566.
ABSTRACT | FULL TEXT  

Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
Schapira and Olanow
JAMA 2004;291:358-364.
ABSTRACT | FULL TEXT